Skip to content
DataLookout
Menu

LINKER-SMM2NCT07393282

A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)

StatusRecruiting
PhasePhase 3
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 11 versions: 11 with changes below. See every version on ClinicalTrials.gov ↗

  1. Minor Trial sites expanded: 27 → 33 locations
  2. Minor Trial sites expanded: 19 → 27 locations
  3. Minor Study sites: 19 to 20
  4. Minor Trial sites expanded: 14 → 19 locations
  5. Notable Eligibility criteria expanded, about 8 words
    • Trial sites expanded: 3 → 14 locations
    • Secondary endpoints: details revised at 5 of 24 entries
Show 3 earlier versionsHide 3 earlier versions
  1. Minor Study sites revised (3)v6
  2. Minor Study sites: 2 to 3v5
  3. Minor Study sites: 1 to 2v4
  1. Notable Recruitment openedv3 Show 4 more changesShow less
    • Study sites: 0 to 1
    • Primary and study completion dates: Jul 22, 2033 to Jul 27, 2033
    • Start date changed from estimate of Mar 25, 2026 to May 21, 2026
    • Secondary endpoints revised (24)
  2. Notable Eligibility criteria expanded, about 3 words
    • Secondary endpoints: 30 to 24
    v2
  3. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Clinical Progression Free Survival (PFS) per International Myeloma Working Group (IMWG) criteria
Timeframe: Up to 5 years
Biochemical PFS per IMWG criteria
Timeframe: Up to 5 years

Secondary (24)

Achievement of Minimal Residual Disease (MRD) Complete Response (CR) at 10^-5 per IMWG criteria
Time to death
Overall Response Rate (ORR) of Partial Response or better (≥PR) per IMWG criteria
Best Overall Response (BOR) per IMWG criteria
Achievement of MRD-negativity
Show 19 moreShow less
Sustained MRD-negativity
Duration of MRD-negative CR
Duration Of Response (DOR) per IMWG criteria
Occurrence of Treatment-Emergent Adverse Events (TEAEs)
Severity of TEAEs
Occurrence of Serious Adverse Events (SAEs)
Change from baseline score in European Organization for Research and Treatment of Cancer Quality of Life Core Questionnaire 30 (EORTC QLQ-C30) Global Health Status (GHS)/Quality of Life (QoL) scale
Change from baseline score in EORTC QLQ-C30 physical functioning scale
Change from baseline score in EORTC QLQ-C30 role functioning scale
Change from baseline score in EORTC QLQ-C30 emotional functioning scale
Change from baseline score in EORTC QLQ-C30 pain scale
Change from baseline score in EORTC QLQ-C30 fatigue scale
Change from baseline score in EORTC IL478 future perspectives scale
Change from baseline score in EuroQoL-5 Dimensions 5-Level Questionnaire Visual Analogue Scale (EQ-5D-5L VAS )
Functional Assessment of Cancer Therapy (FACIT)- Item Global Population 5 (GP5) responses
Change from baseline in FACIT- Item GP5 score
Concentrations of linvoseltamab in serum
Occurrence of Anti-Drug Antibodies (ADAs) to linvoseltamab in serum
Magnitude of ADA to linvoseltamab in serum

Arms and interventions

LinvoseltamabExperimental
DaratumumabActive comparator

Drugs: Linvoseltamab, Daratumumab

Sites

33 sites in 6 countries

United States 9, South Korea 7, United Kingdom 6, Japan 5, France 4, Poland 2